Unilife Corporation Appoints Christopher Naftzger as General Counsel, Corporate Secretary and Chief Compliance Officer

LEWISBERRY, Pa., July 7 /PRNewswire-FirstCall/ -- Unilife Corporation (“Unilife” or “Company”) (Nasdaq: UNIS, ASX: UNS), today announced that it has expanded its management team to include Christopher Naftzger as the Company’s General Counsel, Corporate Secretary and Chief Compliance Officer. Mr. Naftzger will provide the management team and Board of Directors of Unilife with counsel on all international, legal and government matters as well as corporate finance and SEC regulation.

Prior to joining Unilife, Mr. Naftzger served on the senior management team as assistant general counsel and assistant secretary of Chesapeake Corporation, a global supplier of packaging to the pharmaceutical, healthcare and consumer industries. While at Chesapeake, Mr. Naftzger participated in all Board of Directors and Board Committee meetings as well as coordinated with the global sales team on negotiations for multi-year / multi-product supply contracts with a number of leading pharmaceutical and healthcare companies.

Mr. Naftzger has also served as the senior counsel at Koch Industries, Inc, the second largest privately held company in the U.S. with revenues of approximately $98 billion in 2008, and as a partner at Blank Rome LLP, a full service international law and government affairs firm. He holds a juris doctorate from Willamette University College of Law in Oregon, and a bachelor’s degree from Hampden-Sydney College in Virginia.

Mr. Alan Shortall, Chief Executive Officer of Unilife, said, “We are pleased to add Chris to our executive team. We believe his extensive knowledge and experience as a lawyer and corporate secretary will be an asset as we continue to expand the Company, and build commercial relationships with a number of pharmaceutical customers. His appointment should also help to reduce outside legal costs in areas such as SEC compliance and contract negotiations.”

About Unilife Corporation

Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in our registration statement on Form 10 and those described from time to time in our periodic reports which we file with the Securities and Exchange Commission.

General: UNIS-G

SOURCE Unilife Corporation